Disclosed herein are compounds of formula (I) that may be specific to PPAR and/or EGF receptors, and methods of making and using same. wherein X is C 1 -C 3 alkylene, optionally substituted with one, two or three substituents selected from halogen or hydroxyl； R 1 is selected from the group consisting of C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl； R 2 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl； R 3 is independently selected, for each occurrence from the group consisting of hydrogen, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, cyano, C 3 -C 6 cycloalkyl, halogen, hydroxyl, and nitro； R 4 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl； R 5 is hydrogen C 1 -C 6 alkyl； or pharmaceutically acceptable salts or N-oxides thereof.
